Phase II Trials of Alzheimer’s Drug Begins
MK-8931, a newly developed drug against the Alzheimer's disease, has begun with the Phase II trials in which the patients with the different level of disease will be given the drug to check the safety and effectiveness of the same.
The research, in its phase II, will consider the tests on 200 patients while in the next phase trials i. e. phase III, it will check the effect on 1,700 patients. The drug is reported to be the first of its kind that is moving towards the higher stages of the medical research.
If the drug succeeds in the trials, it will be available for use widely within next two to three years. It is believed to slow down the effect of brain destroying disease and even stop it. The success of research will send out waves of happiness among the people with the disease.
It is believed to bring out revolution in the world of medicines. Currently, there are over 5.4 million patients with Alzheimer's in the US and the number will soar to 16 million by 2050. The cost will then increase from current $200 billion to $1.1 trillion in 2050, as estimated. Merck & Co Inc is the company behind the new drug.
New Zealand News
- What Does Phasing Out Cheques Tell Us About Finance in New Zealand?
- South Korean casino operator GKL closes third casino amid soaring cases of COVID-19
- Top Live Casinos in India and Pure Casino Signup Offer
- Independent MP Justin Field making efforts to prevent NSW from compensating Crown Resorts
- President-elect Biden’s Climate Plan to provide big boost to EVs and green power